Glenmark board to meet Nov 5 to consider Q2 FY26 results

Results View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹2198.50

prior close

₹2130.30

announcement price

In-mkt

timing

Nifty Midcap 150market-2.1%+0.6% vs market

Pharmaceuticals peers, median of 170sector-1.6%+0.1% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.0

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-2.1+0.6-1.6+0.1

Next day

+1.2-1.0+2.3-0.5+1.7

+3.1-0.1+3.2+1.5+1.5

+4.6pendingpending+2.5+2.1

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Glenmark Pharmaceuticals has informed stock exchanges that its Board of Directors will meet on Thursday, November 5, 2026, to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half year ended September 30, 2026. The results will be submitted to exchanges after the meeting and published on the company website and in newspapers. The trading window for designated persons remains closed from October 1, 2026 till November 7, 2026 and reopens on November 8, 2026.

Likely market impact

Routine pre-results announcement. Investors should watch for Q2 and H1 FY26 numbers on Nov 5; no new business action implied.